Martin McMahon, PhD
Professor Emeritus
HDF Comprehensive Cancer Ctr
School of Medicine

Education & Training

Show all (1) Hide

• Postdoctoral Studies Graduate Division University of California, San Francisco

Grants and Projects

Show all (4) Hide

• Cancer Center Support Grant, NIH, 1999-2023
• Studying the initiation, progression and therapy of lung cancer in mouse models, NIH, 2007-2021
• Targeting Oncogenic BRAF And PI3'-Kinase Signaling For Melanoma Therapy, NIH, 2013-2018
• Regulation of apoptosis by mutationally activated B-Raf, NIH, 2005-2010

Publications (88)

Top publication keywords:
CarcinogenesisMAP Kinase Kinase 2Phosphatidylinositol 3-KinasesMAP Kinase Signaling SystemMelanomaLung NeoplasmsProto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesProtein Kinase InhibitorsMitogen-Activated Protein Kinase KinasesCell Transformation, Neoplasticraf KinasesProto-Oncogene Proteins p21(ras)MAP Kinase Kinase 1PTEN Phosphohydrolase

• Genetic Silencing of AKT Induces Melanoma Cell Death via mTOR Suppression.
  Molecular cancer therapeutics 2024 Parkman GL, Turapov T, Kircher DA, Burnett WJ, Stehn CM, O'Toole K, Culver KM, Chadwick AT, Elmer RC, Flaherty R, Stanley KA, Foth M, Lum DH, Judson-Torres RL, Friend JE, VanBrocklin MW, McMahon M, …
• PTEN phosphatase inhibits metastasis by negatively regulating the Entpd5/IGF1R pathway through ATF6.
  iScience 2023 Yu Y, Dai M, Huang L, Chen W, Yu E, Mendoza A, Michael H, Khanna C, Bosenberg M, McMahon M, Merlino G
• Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis.
  Cancer research 2022 Vaishnavi A, Juan J, Jacob M, Stehn C, Gardner EE, Scherzer MT, Schuman S, Van Veen JE, Murphy B, Hackett CS, Dupuy AJ, Chmura SA, van der Weyden L, Newberg JY, Liu A, Mann K, Rust AG, Weiss WA, …
• The role of PI3'-lipid signalling in melanoma initiation, progression and maintenance.
  Experimental dermatology 2021 Parkman GL, Foth M, Kircher DA, Holmen SL, McMahon M
• Melanoma models for the next generation of therapies.
  Cancer cell 2021 Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, Bosenberg M, Ceol CJ, Burd CE, Chi P, Herlyn M, Holmen SL, Karreth FA, Kaufman CK, Khan S, Kobold S, Leucci E, Levy C, …

Show all (83 more) Hide

• Model-dependent outcomes: Sex as a biological variable in preclinical mouse models of melanoma.
  Pigment cell & melanoma research 2020 Parkman GL, Kircher DA, Stehn CM, McMahon M, Holmen SL
• Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Truong A, Yoo JH, Scherzer MT, Sanchez JMS, Dale KJ, Kinsey CG, Richards JR, Shin D, Ghazi PC, Onken MD, Blumer KJ, Odelberg SJ, McMahon M
• Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer.
  Cell reports 2020 Vaishnavi A, Scherzer MT, Kinsey CG, Parkman GL, Truong A, Ghazi P, Schuman S, Battistone B, Garrido-Laguna I, McMahon M
• RAC1mutation is not a predictive biomarker for PI3'-kinase-β-selective pathway-targeted therapy.
  Pigment cell & melanoma research 2020 Foth M, Parkman G, Battistone B, McMahon M
• Mutationally-activated PI3'-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase.
  eLife 2019 van Veen JE, Scherzer M, Boshuizen J, Chu M, Liu A, Landman A, Green S, Trejo C, McMahon M
• AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.
  Molecular cancer research : MCR 2019 Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, Stehn CM, Strain SC, Grossmann AH, Duffy KL, Boucher KM, McMahon M, Davies MA, Mendoza MC, VanBrocklin MW, Holmen SL
• Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
  Nature medicine 2019 Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW, Cavalieri CC, Rehbein KM, Cutler SL, …
• Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
  Nature medicine 2019 Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW, Cavalieri CC, Rehbein KM, Cutler SL, …
• Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
  American journal of medical genetics. Part A 2018 Rauen KA, Schoyer L, Schill L, Stronach B, Albeck J, Andresen BS, Cavé H, Ellis M, Fruchtman SM, Gelb BD, Gibson CC, Gripp K, Hefner E, Huang WYC, Itkin M, Kerr B, Linardic CM, McMahon M, Oberlander B…
• PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.
  Pigment cell & melanoma research 2017 Silva JM, Deuker MM, Baguley BC, McMahon M
• BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis.
  eLife 2017 Sakamoto N, Feng Y, Stolfi C, Kurosu Y, Green M, Lin J, Green ME, Sentani K, Yasui W, McMahon M, Hardiman KM, Spence JR, Horita N, Greenson JK, Kuick R, Cho KR, Fearon ER
• Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model.
  Oncotarget 2016 Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK
• P2A-Fluorophore Tagging of BRAF Tightly Links Expression to Fluorescence In Vivo.
  PloS one 2016 van Veen JE, Pringle DR, McMahon M
• The state of melanoma: challenges and opportunities.
  Pigment cell & melanoma research 2016 Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, …
• PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
  Cancer research 2015 Green S, Trejo CL, McMahon M
• AKT1 Activation Promotes Development of Melanoma Metastases.
  Cell reports 2015 Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL
• Intermittent dosing in melanoma.
  Clinical advances in hematology & oncology : H&O 2015 McMahon M
• TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.
  Cancer research 2015 Shai A, Dankort D, Juan J, Green S, McMahon M
• Rational targeting of BRAF and PI3-Kinase signaling for melanoma therapy.
  Molecular & cellular oncology 2015 Deuker MM, McMahon M
• Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma.
  Nature genetics 2015 Mann MB, Black MA, Jones DJ, Ward JM, Yew CC, Newberg JY, Dupuy AJ, Rust AG, Bosenberg MW, McMahon M, Print CG, Copeland NG, Jenkins NA
• The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
  Nature genetics 2015 Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson …
• mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.
  Cancer cell 2015 Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, …
• PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.
  Cancer discovery 2014 Deuker MM, Marsh Durban V, Phillips WA, McMahon M
• Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.
  Nature reviews. Cancer 2014 Holderfield M, Deuker MM, McCormick F, McMahon M
• Cancer biology: Enzyme meets a surprise target.
  Nature 2014 Deuker MM, McMahon M
• Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
  Cancer immunology research 2014 Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA
• Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
  Molecular cancer research : MCR 2014 Charles RP, Silva J, Iezza G, Phillips WA, McMahon M
• Isolation and molecular characterization of circulating melanoma cells.
  Cell reports 2014 Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, …
• p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
  Proceedings of the National Academy of Sciences of the United States of America 2014 McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM, Jacks T
• Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors.
  Genes & development 2014 Juan J, Muraguchi T, Iezza G, Sears RC, McMahon M
• The fastest Western in town: a contemporary twist on the classic Western blot analysis.
  Journal of visualized experiments : JoVE 2014 Silva JM, McMahon M
• BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
  Molecular cancer research : MCR 2014 Silva JM, Bulman C, McMahon M
• Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
  The Journal of clinical investigation 2013 Marsh Durban V, Deuker MM, Bosenberg MW, Phillips W, McMahon M
• Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720.
  Molecular cancer research : MCR 2013 Kamata T, Dankort D, Kang J, Giblett S, Pritchard CA, McMahon M, Leavitt AD
• Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.
  Proceedings of the National Academy of Sciences of the United States of America 2013 Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen CH, Bosenberg MW, McMahon M, Cantley LC, Zheng B
• Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation.
  Human molecular genetics 2013 Goodwin AF, Tidyman WE, Jheon AH, Sharir A, Zheng X, Charles C, Fagin JA, McMahon M, Diekwisch TG, Ganss B, Rauen KA, Klein OD
• Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
  Cancer research 2013 Trejo CL, Green S, Marsh V, Collisson EA, Iezza G, Phillips WA, McMahon M
• Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors.
  Cancer discovery 2013 Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, McMahon M, White E
• Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
  Nature 2013 Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD
• Elucidating distinct roles for NF1 in melanomagenesis.
  Cancer discovery 2012 Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K
• Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma.
  The Journal of pathology 2012 Mito JK, Min HD, Ma Y, Carter JE, Brigman BE, Dodd L, Dankort D, McMahon M, Kirsch DG
• An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.
  Nature 2012 Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, …
• The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
  Genes & development 2012 Andreadi C, Cheung LK, Giblett S, Patel B, Jin H, Mercer K, Kamata T, Lee P, Williams A, McMahon M, Marais R, Pritchard C
• Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.
  Molecular cancer research : MCR 2012 Gysin S, Paquette J, McMahon M
• B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer.
  Cancer research 2012 Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, McMahon M, Califano A, Shen MM, Abate-Shen C
• Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord.
  Development (Cambridge, England) 2012 Tien AC, Tsai HH, Molofsky AV, McMahon M, Foo LC, Kaul A, Dougherty JD, Heintz N, Gutmann DH, Barres BA, Rowitch DH
• A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.
  Cancer discovery 2012 Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M
• Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy.
  Proceedings of the National Academy of Sciences of the United States of America 2012 Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH
• Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.
  Genes & development 2012 Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS
• E-cadherin regulates the behavior and fate of epithelial stem cells and their progeny in the mouse incisor.
  Developmental biology 2012 Li CY, Cha W, Luder HU, Charles RP, McMahon M, Mitsiadis TA, Klein OD
• MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
  Cancer research 2012 Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M
• β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.
  Cancer cell 2011 Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M, Bosenberg M
• Control of mitotic spindle angle by the RAS-regulated ERK1/2 pathway determines lung tube shape.
  Science (New York, N.Y.) 2011 Tang N, Marshall WF, McMahon M, Metzger RJ, Martin GR
• Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.
  Cancer research 2011 Charles RP, Iezza G, Amendola E, Dankort D, McMahon M
• Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.
  American journal of medical genetics. Part C, Seminars in medical genetics 2011 Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, Melese T, Munster PN, Nadaf S, Packer RJ, Sebolt-Leopold J, Viskochil DH
• Parsing out the complexity of RAF inhibitor resistance.
  Pigment cell & melanoma research 2011 McMahon M
• RAF translocations expand cancer targets.
  Nature medicine 2010 McMahon M
• Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.
  Science translational medicine 2010 Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM
• Characterization of melanoma cells capable of propagating tumors from a single cell.
  Cancer research 2010 Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V, Bosenberg MW
• Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
  American journal of medical genetics. Part A 2010 Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, Gutmann DH, McMahon M, Guerra C, …
• Down-regulation of Cdx2 in colorectal carcinoma cells by the Raf-MEK-ERK 1/2 pathway.
  Cellular signalling 2009 Krueger F, Madeja Z, Hemberger M, McMahon M, Cook SJ, Gaunt SJ
• Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008.
  Pigment cell & melanoma research 2009 Agarwala SS, Becker JC, Eggermont AM, Flaherty KT, Garbe C, Goldstein AM, Halpern A, Kashani-Sabet M, Hauschild A, Kirkwood JM, Leachman S, Lorigan P, McMahon M, Messina J, Ribas A, Samlowski WE, …
• Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
  Nature genetics 2009 Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, You MJ, DePinho RA, McMahon M, Bosenberg M
• Meeting report: fourth international congress of the Society for Melanoma Research.
  Pigment cell & melanoma research 2008 Fisher DE, Medrano EE, McMahon M, Soengas MS, Schuchter L, Wolchok JD, Merlino G
• Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
  Pigment cell & melanoma research 2007 Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, McMahon M
• A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
  Genes & development 2007 Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M
• A model of intussusceptive angiogenesis.
  Novartis Foundation symposium 2007 Levin M, Ewald AJ, McMahon M, Werb Z, Mostov K
• Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells.
  Proceedings of the National Academy of Sciences of the United States of America 2006 Banerjee A, Gugasyan R, McMahon M, Gerondakis S
• Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
  Cancer research 2005 Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwäble J, Buerger H, Müller-Tidow C, Choudhary C, McMahon M, Berdel WE, Serve H
• Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines.
  Genes, chromosomes & cancer 2005 Gysin S, Rickert P, Kastury K, McMahon M
• Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines.
  Cell cycle (Georgetown, Tex.) 2005 Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Franklin RA, Bertrand FE, McMahon M, McCubrey JA
• Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
  Cancer research 2005 Gysin S, Lee SH, Dean NM, McMahon M
• Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor.
  Molecular and cellular biology 2005 Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K
• Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT.
  Molecular and cellular biology 2004 Mirza AM, Gysin S, Malek N, Nakayama K, Roberts JM, McMahon M
• Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells.
  Oncogene 2004 McCubrey JA, Shelton JG, Steelman LS, Franklin RA, Sreevalsan T, McMahon M
• Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion.
  The Journal of biological chemistry 2004 Silletti S, Yebra M, Perez B, Cirulli V, McMahon M, Montgomery AM
• Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf.
  The Journal of clinical investigation 2004 Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ, Young SG
• DeltaRaf-1:ER* bypasses the cyclic AMP block of extracellular signal-regulated kinase 1 and 2 activation but not CDK2 activation or cell cycle reentry.
  Molecular and cellular biology 2003 Balmanno K, Millar T, McMahon M, Cook SJ
• Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis.
  Nature 2003 Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M
• Ras-induced serine phosphorylation of the focal adhesion protein paxillin is mediated by the Raf-->MEK-->ERK pathway.
  Experimental cell research 2003 Woodrow MA, Woods D, Cherwinski HM, Stokoe D, McMahon M
• Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells.
  Cancer research 2003 Anders M, Christian C, McMahon M, McCormick F, Korn WM
• Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.
  Oncogene 2003 Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW, Franklin RA, Pohnert SC, Mirza AM, McMahon M, McCubrey JA
• Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells.
  Experimental cell research 2002 Venetsanakos E, Mirza A, Fanton C, Romanov SR, Tlsty T, McMahon M